FNY Investment Advisers’s Sutro Biopharma STRO Stock Holding History

FNY Investment Advisers’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33K	Hold	1,000	–	–	0.01%	475
2026 Q1	$24K	Hold	1,000	–	–	0.01%	450
2025 Q4	$11K	Hold	1,000	–	–	﹤0.01%	650
2025 Q3	$8K	Buy	+1,000	New	+$8.51K	﹤0.01%	848
2021 Q1	–	Sell	-700	Closed	-$151K	–	995
2020 Q4	$151K	Buy	+700	New	+$116K	0.04%	233
2019 Q3	–	Sell	-147	Closed	-$16K	–	1162
2019 Q2	$16K	Buy	+147	New	+$16.2K	﹤0.01%	507

Other funds holding STRO

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

OCWP

Owl Creek Wealth Partners Denver, Colorado $342M AUM

PWA

Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

FNY Investment Advisers's STRO Position: Q2 2026 in Review

FNY Investment Advisers held its Sutro Biopharma (STRO) position steady in Q2 2026 at 1,000 shares worth $33K. The position accounts for 0.01% of the portfolio, ranked #475.

FNY Investment Advisers first reported a position in STRO in Q2 2019 and has held it in 6 quarters since. The position peaked at $151K in Q4 2020. 5 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

FNY Investment Advisers held 1,000 shares of Sutro Biopharma worth $33K as of Q2 2026.
FNY Investment Advisers left its Sutro Biopharma share count unchanged in Q2 2026.
Sutro Biopharma made up 0.01% of FNY Investment Advisers's portfolio in Q2 2026, its #475 holding.
FNY Investment Advisers first reported a position in Sutro Biopharma in Q2 2019 and has held it in 6 quarters since.
FNY Investment Advisers's Sutro Biopharma position peaked at $151K in Q4 2020.
5 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.